title: Stable stroke incidence rates but improved case-fatality in Dijon, France, from 1985 to 2004.
abstract: OBJECTIVE
  With the progress in stroke prevention, it is important to evaluate the epidemiological trends of strokes over a long period and from a nonselected population-based perspective.
  
  
  METHODS
  We estimated changes in incidence, case-fatality rates, severity, risk factors and prestroke use of preventive treatments for first-ever strokes, from a continuous 20-year well-defined population-based registry, from 1985 to 2004.
  
  
  RESULTS
  We recorded 3142 ischemic strokes, 341 primary cerebral hemorrhages and 74 subarachnoid hemorrhages. During the 20-year study, the age at first stroke onset increased by 5 years in men and 8 years in women. Comparing the 1985 to 1989 and the 2000 to 2004 periods, age- and sex-standardized incidences of first-ever strokes were stable except for lacunar strokes whose incidence significantly increased (P=0.01) and for cardioembolic stroke whose incidence significantly decreased (P=0.01). Twenty-eight-day case-fatality rates decreased significantly mainly for lacunar strokes (P=0.05) and for primary cerebral hemorrhages (P=0.03). The proportion of hypercholesterolemia and diabetes significantly increased (P<0.01). In contrast, the proportion of myocardial infarction significantly decreased (P=0.02). Prestroke antiplatelets and anticoagulants treatment significantly increased (P<0.01).
  
  
  CONCLUSIONS
  The age- and sex-standardized incidences of first strokes in Dijon have been stable over the past 20 years and were associated with an increase in age at stroke onset, a decrease in case-fatality rates, and an increased use of antiplatelet treatments.
authors.affiliation: Stroke Registry of Dijon (Inserm and Institut de Veille Sanitaire), Faculty of Medicine and University Hospital of Dijon, France.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Benatru
authors.forename: Olivier
authors.initials: O
authors.lastname: Rouaud
authors.forename: Jérôme
authors.initials: J
authors.lastname: Durier
authors.forename: Fabienne
authors.initials: F
authors.lastname: Contegal
authors.forename: Grégory
authors.initials: G
authors.lastname: Couvreur
authors.forename: Yannick
authors.initials: Y
authors.lastname: Bejot
authors.forename: Guy Victor
authors.initials: GV
authors.lastname: Osseby
authors.forename: Douraïeb
authors.initials: D
authors.lastname: Ben Salem
authors.forename: Frédéric
authors.initials: F
authors.lastname: Ricolfi
authors.forename: Thibault
authors.initials: T
authors.lastname: Moreau
authors.forename: Maurice
authors.initials: M
authors.lastname: Giroud
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000453:epidemiology; D016893:Carotid Stenosis / Q000453:epidemiology; D015897:Comorbidity; D003920:Diabetes Mellitus / Q000453:epidemiology; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D006937:Hypercholesterolemia / Q000453:epidemiology; D006973:Hypertension / Q000453:epidemiology; D015994:Incidence; D002546:Ischemic Attack, Transient / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009017:Morbidity / Q000639:trends; D009026:Mortality / Q000639:trends; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012042:Registries; D012307:Risk Factors; D012907:Smoking / Q000453:epidemiology; D020521:Stroke / Q000453:epidemiology* / Q000401:mortality / Q000517:prevention & control; D014715:Vertebrobasilar Insufficiency / Q000453:epidemiology
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors